|
業務類別
|
Biotechnology |
|
業務概覽
|
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants. |
| 公司地址
| 15 Independence Boulevard, Suite 210, Warren, NJ, USA, 07059 |
| 電話號碼
| +1 877 838-6434 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.tevogen.com |
| 員工數量
| 18 |
| Mr. Sadiq Khan |
Chief Commercial Officer |
-- |
31/03/2026 |
| Dr. Neal Flomenberg, M.D. |
Chief Scientific Officer and Global Research and Development Lead |
美元 350.00K |
31/03/2026 |
| Dr. Ryan Saadi, M.D.,M.P.H. |
Chairman of the Board and Chief Executive Officer |
美元 501.00K |
31/03/2026 |
| Mr. Kirti Desai |
Chief Financial Officer and Principal Accounting Officer |
美元 300.00K |
31/03/2026 |
|
|
| Ms. Susan M. Podlogar |
Independent Director |
31/03/2026 |
| Mr. Victor Sordillo |
Director |
31/03/2026 |
| Dr. Curtis Patton |
Director |
31/03/2026 |
| Dr. Ryan Saadi, M.D.,M.P.H. |
Chairman of the Board and Chief Executive Officer |
31/03/2026 |
| Mr. Jeffrey Feike |
Director |
31/03/2026 |
| Dr. Keow Lin Goh |
Director |
31/03/2026 |
|
|
|
|
